Effect of PD-L1 testing on the cost-effectiveness and budget impact of pembrolizumab for advanced urothelial carcinoma of the bladder in the United States

Author:

Criss Steven D.,Weaver Davis T.,Sheehan Deirdre F.,Lee Richard J.,Pandharipande Pari V.,Kong Chung YinORCID

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference40 articles.

1. Cancer statistics, 2018;Siegel;CA Cancer J Clin,2018

2. The 2016 WHO classification of tumours of the urinary system and male genital organs-Part B: prostate and bladder tumours;Humphrey;Eur Urol,2016

3. Histologic variants of urothelial bladder cancer and nonurothelial histology in bladder cancer;Chalasani;Can Urol Assoc J,2009

4. Pharma queues up for checkpoint inhibitor collaborations [Electronic Article];Extance;Chem World,2015

5. FDA Approves Merck's KEYTRUDA® (pembrolizumab) for Certain patients with locally advanced or metastatic urothelial carcinoma, a type of bladder cancer [press release],2017

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3